Figure 7. The results of animal experiments confirmed that HOXC-AS2 can promote hypopharyngeal cancer progression. (A–C) Morphological characteristics of subcutaneous xenografts (A), tumor weight (B), and tumor size (C) on day 35 in mice injected with LV-KDNC-HOXC-AS2-D-562 cells and LV-KD-HOXC-AS2-D-562 cells (five mice per group). (D–F) Morphological characteristics of subcutaneous xenografts (D), tumor weight (E), and tumor size (F) on day 35 in mice injected with LV-KD-HOXC-AS2 +OE-P62-D-562 cells and LV-KD-HOXC-AS2-D-562 cells (five mice per group). (G–I) IHC analysis of P62 protein expression in tumors from the LV-KDNC-HOXC-AS2, LV-KD-HOXC-AS, and LV-KD-HOXC-AS2 +OE-P62 groups. (J–L) IHC analysis of NF-kB protein expression in tumors from the LV-KDNC-HOXC-AS2, LV-KD-HOXC-AS, and LV-KD-HOXC-AS2 +OE-P62 groups. (M–O) IHC analysis of p-p65 protein expression in tumors from the LV-KDNC-HOXC-AS2, LV-KD-HOXC-AS, and LV-KD-HOXC-AS2 +OE-P62 groups.